Pharmaceuticals News and Research

RSS

Prolong Pharmaceuticals receives $30 million from private investor group

Prolong Pharmaceuticals today announced that the company has received a commitment of $30 million in funding from a private investor group. The monies will be dedicated to the company's continuing research and development efforts and clinical programs targeting anemias resulting from oxygen deficiency.

15 Oct 2010

Acetadote Injection is now commercially available in Australia

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Survey: 94% of psychiatric nurses are dedicated in providing care for people with mental illness

According to a new survey sponsored by Janssen-, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 94 percent of psychiatric nurses feel very or extremely involved in providing care for people with mental illness. Although some psychiatric nurses believe that their specialty is as difficult as or more difficult than oncology nursing, or emergency nursing, one-third would prefer to be more involved in patient care than they are now. The survey also revealed that psychiatric nurses believe their work affects patient care, with more than 90 percent of psychiatric nurses viewing the time they spend with patients as very important to patient satisfaction with their overall healthcare experience. A majority of the nurses strongly agree that their involvement helps to achieve better outcomes for patients living with mental illness.

14 Oct 2010

Real-time data access can improve quality and efficiency of drug development

Technologies to capture and view clinical trial data in real time offer great potential to enhance patient safety, strengthen trial quality and accelerate drug development, but they also require new guidelines to ensure trial integrity, according to the white paper "Using Real-Time Data to Drive Better Decisions, Faster" released today by Quintiles, the world's leading biopharmaceutical services company.

14 Oct 2010

New filtering technology kills disease-causing bacteria without clogging

With almost one billion people lacking access to clean, safe drinking water, scientists are reporting development and successful initial tests of an inexpensive new filtering technology that kills up to 98 percent of disease-causing bacteria in water in seconds without clogging. A report on the technology appears in Nano Letters, a monthly American Chemical Society journal.

14 Oct 2010

PPC offers on-site medication dispensing programs for hospitals

The fastest-growing privately held healthcare company in the country is building its business by building in-office medication dispensing programs for physicians and hospitals in 10 states. Incorporated just five years ago, Physicians' Pharmaceutical Corporation (PPC) placed No. 1 among health companies and No. 15 overall on the 2010 Inc. 5000 list of fastest-growing companies.

14 Oct 2010

Top biopharma leaders to share strategies at Windhover's 2nd PharmAsia Summit

Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and The Pink Sheet, today announced the agenda for Windhover's 2nd PharmAsia Summit (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

14 Oct 2010

LFA announces award of new grants for lupus research

The Lupus Foundation of America, Inc. (LFA) today announced the awarding of six new research grants to address gaps in the science and understanding of key areas of lupus research, including pediatric lupus, reproductive health issues in people with lupus, lupus nephritis (kidney involvement), and neuropsychiatric lupus, which affects the brain and nervous system.

14 Oct 2010

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.

14 Oct 2010

Dyadic International receives sixth USPTO patent

Dyadic International, Inc. a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office.

14 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

AusBiotech 2010 set to demystify the impact of US Healthcare Reforms on Australian biotech

Australian biotechnology and pharmaceutical companies are seeking to understand the implications of the US Healthcare Reform Bill, says Australia’s biotechnology industry organisation, AusBiotech. In order to remain compliant and globally competitive, biotechs need to identify and work within a gamut of new requirements, complications and hurdles imposed by this new regulatory environment.

13 Oct 2010

Global project to find biological activity in sea organisms suitable for pharmaceutical products

Researchers at the Faculty of Pharmacy at the University of Helsinki are co-ordinating an extensive project which aims to find biological activity from among organisms in the sea which would be suitable for use as a basis for pharmaceutical products. Interesting compounds isolated from organisms in the sea are chemically modified to be more suitable for medical purposes.

13 Oct 2010

Shire acquires 99.21% of Movetis shares

Shire plc, the global specialty biopharmaceutical company, announces that its wholly owned subsidiary Shire Holdings Luxembourg S.a.r.l. acquired 99.21% of the shares of Movetis NV on October 12, 2010, following a successful tender offer launched in September 2010.

13 Oct 2010

Employees need to review health insurance plans during open enrollment

Open enrollment, starting in October for most companies, allows employees to make changes to their benefits for the coming year. It's often the only time during the year that employees can make changes to their health insurance plans, and the passage of the recently enacted healthcare reform means that Americans could be facing more changes to their existing health insurance plans.

13 Oct 2010

Medical Exchange announces next generation of continuing medical education events

Medical Exchange, an innovative provider of medical education solutions for the health care industry, today announced the next generation of continuing medical education events with the launch of collaborativeCARE Conference (C3).

13 Oct 2010

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.

13 Oct 2010